Design and Synthesis of some Benzothiazole Analogs as A2A Receptor Antagonist

The A receptor is expressed in the brain, where it has important roles in the regulation of glutamate and dopamine release, making it a potential A2A therapeutic target for the treatment of conditions such as insomnia, pain, depression, drug addiction and Parkinson's disease. Molecular Modelling Study with respect to Docking is frequently used to predict the binding orientation of drug candidates to their protein targets in turn predict the affinity and activity of the small molecule. On the basis of docking study, some compounds are proceeded to synthesize. Molecular docking studies of designed A receptor antagonist was validated on the basis of docking score obtained by re-docking of co-crystallized ligand of A2A receptor (PDB ID: 3EML) as well as all synthesized compound was validated by spectral analysis.